BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/18/2021 8:08:20 AM | Browse: 908 | Download: 1927
Publication Name World Journal of Gastroenterology
Manuscript ID 63181
Country United Kingdom
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Molecular advances in pancreatic cancer: A genomic, proteomic and metabolomic approach
Manuscript Source Invited Manuscript
All Author List Srujan Rajesh, Michael J Cox and Franscois Runau
ORCID
Author(s) ORCID Number
Srujan Rajesh http://orcid.org/0000-0002-1313-1101
Michael J Cox http://orcid.org/0000-0002-3264-6709
Franscois Runau http://orcid.org/0000-0001-6778-459X
Funding Agency and Grant Number
Corresponding Author Franscois Runau, FRCS (Gen Surg), PhD, Academic Fellow, Surgeon, Department of General Surgery, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, United Kingdom. franscois_gerald@yahoo.com
Key Words Pancreatic ductal adenocarcinoma, Pancreatic adenocarcinoma; Genomic; Proteomic; Metabolomic
Core Tip Treatment for pancreatic ductal adenocarcinoma is limited by the severity of the pathology, limited biomarkers and late presentation of patients. Utilising genomic, proteomic and metabolomic research into pancreatic ductal adenocarcinoma has provided insight into understanding the disease process as well as providing suitable markers of diagnosis and treatment to improve clinical outcomes.
Publish Date 2021-08-18 08:08
Citation Rajesh S, Cox MJ, Runau F. Molecular advances in pancreatic cancer: A genomic, proteomic and metabolomic approach. World J Gastroenterol 2021; 27(31): 5171-5180
URL https://www.wjgnet.com/1007-9327/full/v27/i31/5171.htm
DOI https://dx.doi.org/10.3748/wjg.v27.i31.5171
Full Article (PDF) WJG-27-5171.pdf
Full Article (Word) WJG-27-5171.docx